IUPAC/Chemical Name
(R)-2-methoxy-3-(octadecyloxy)propyl ((1S,2R,3S,4R,6R)-2,3,4-trihydroxy-6-methoxycyclohexyl) hydrogen phosphate
InChi Key
NRLLDDPUQZQEDV-MWJQJBPESA-N
InChi Code
InChI=1S/C29H59O10P/c1-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20-37-22-24(35-2)23-38-40(33,34)39-29-26(36-3)21-25(30)27(31)28(29)32/h24-32H,4-23H2,1-3H3,(H,33,34)/t24-,25-,26-,27+,28-,29-/m1/s1
SMILES Code
O=P(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)C[C@H]1OC)(OC[C@H](OC)COCCCCCCCCCCCCCCCCCC)O
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
Preparing Stock Solutions
The following data is based on the
product
molecular weight
598.75
Batch specific molecular weights may vary
from batch to batch
due to the degree of hydration, which will
affect the solvent
volumes required to prepare stock solutions.
| Concentration / Solvent Volume / Mass |
1 mg |
5 mg |
10 mg |
| 1 mM |
1.15 mL |
5.76 mL |
11.51 mL |
| 5 mM |
0.23 mL |
1.15 mL |
2.3 mL |
| 10 mM |
0.12 mL |
0.58 mL |
1.15 mL |
| 50 mM |
0.02 mL |
0.12 mL |
0.23 mL |
1: Sethi G, Ahn KS, Sung B, Kunnumakkara AB, Chaturvedi MM, Aggarwal BB. SH-5, an AKT inhibitor potentiates apoptosis and inhibits invasion through the suppression of anti-apoptotic, proliferative and metastatic gene products regulated by IkappaBalpha kinase activation. Biochem Pharmacol. 2008 Dec 1;76(11):1404-16. doi: 10.1016/j.bcp.2008.05.023. Epub 2008 Jul 5. PMID: 18606397.
2: Krech T, Thiede M, Hilgenberg E, Schäfer R, Jürchott K. Characterization of AKT independent effects of the synthetic AKT inhibitors SH-5 and SH-6 using an integrated approach combining transcriptomic profiling and signaling pathway perturbations. BMC Cancer. 2010 Jun 14;10:287. doi: 10.1186/1471-2407-10-287. PMID: 20546605; PMCID: PMC2895615.
3: Jia T, Cao QQ, Chen XM, Xu FL. Effects of the Akt inhibitor Src-homology 5 on proliferation and apoptosis of the laryngeal squamous cell carcinoma. J Cancer Res Ther. 2018 Jan;14(1):208-212. doi: 10.4103/0973-1482.199454. PMID: 29516987.
4: Sakamoto Y, Suzuki Y, Nakamura A, Watanabe Y, Sekiya M, Roppongi S, Kushibiki C, Iizuka I, Tani O, Sakashita H, Inaka K, Tanaka H, Yamada M, Ohta K, Honma N, Shida Y, Ogasawara W, Nakanishi-Matsui M, Nonaka T, Gouda H, Tanaka N. Fragment- based discovery of the first nonpeptidyl inhibitor of an S46 family peptidase. Sci Rep. 2019 Sep 19;9(1):13587. doi: 10.1038/s41598-019-49984-3. PMID: 31537874; PMCID: PMC6753110.
